114 related articles for article (PubMed ID: 8712579)
41. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
[TBL] [Abstract][Full Text] [Related]
42. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
Welz S; Hehr T; Kollmannsberger C; Bokemeyer C; Belka C; Budach W
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1429-35. PubMed ID: 17692474
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
44. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
45. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of ticarcillin during cisplatin chemotherapy.
Higi M; Essers L; Linzenmeier G; Seeber S
Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):514-6. PubMed ID: 6890947
[TBL] [Abstract][Full Text] [Related]
47. Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients.
Kume M; Yasui H; Yoshikawa Y; Horinouchi M; Higashiguchi K; Kobayashi Y; Kuroda D; Hirano T; Hirai M; Nakamura T
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1537-44. PubMed ID: 22437652
[TBL] [Abstract][Full Text] [Related]
48. Comparison of two dose prediction models for cisplatin.
Desoize B; Dumont P; Manot L; Urien S; Dufour R; Berthiot G
Anticancer Res; 1994; 14(6A):2285-90. PubMed ID: 7825960
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
50. [A method of cisplatin administration with the aid of high-dose bismuth subnitrate, and their pharmacokinetics].
Morikawa T; Kawamura E
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1094-8. PubMed ID: 2730014
[TBL] [Abstract][Full Text] [Related]
51. [Pharmacokinetics of cisplatin and the effect of sodium thiosulfate].
Hayata S; Hitoshi T; Kiyokawa K; Esaki S; Mihashi S; Hirano M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2356-61. PubMed ID: 6541891
[TBL] [Abstract][Full Text] [Related]
52. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
53. [Population pharmacokinetics applied to optimising cisplatin doses in cancer patients].
Ramón-López A; Escudero-Ortiz V; Carbonell V; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(5):392-402. PubMed ID: 22402361
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin pharmacokinetics in children with cancer.
Peng B; English MW; Boddy AV; Price L; Wyllie R; Pearson AD; Tilby MJ; Newell DR
Eur J Cancer; 1997 Oct; 33(11):1823-8. PubMed ID: 9470840
[TBL] [Abstract][Full Text] [Related]
55. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
56. Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates.
Imai T; Fujii K; Shiraishi S; Otagiri M
J Pharm Sci; 1997 Feb; 86(2):244-7. PubMed ID: 9040103
[TBL] [Abstract][Full Text] [Related]
57. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.
Yamamoto N; Tamura T; Maeda M; Ando M; Shinkai T; Eguchi K; Ohe Y; Oshita F; Shiraishi J; Katsumata N
Cancer Chemother Pharmacol; 1995; 36(2):102-6. PubMed ID: 7767944
[TBL] [Abstract][Full Text] [Related]
58. [The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods (report II)--alleviation of renal impairment by bismuth subnitrate combined with ginseng and tang-koui ten].
Takahashi A; Takagi M; Hishida H; Sakamoto Y; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2405-10. PubMed ID: 2665654
[TBL] [Abstract][Full Text] [Related]
59. Renal handling of cis-diamminedichloroplatinum(II).
Jacobs C; Kalman SM; Tretton M; Weiner MW
Cancer Treat Rep; 1980; 64(12):1223-6. PubMed ID: 7193518
[TBL] [Abstract][Full Text] [Related]
60. Kinetics of plasma platinum in a hemodialysis patient receiving repeated doses of cisplatin.
Hirai K; Ishiko O; Sumi T; Kanaoka Y; Ogita S
Oncol Rep; 2000; 7(6):1243-5. PubMed ID: 11032923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
